Sunovion Pharmaceuticals, Inc. donated between $10K and $25K to American Psychiatric Foundation, Inc. in 2018

Jun 01, 2020
Donations and Philanthropy
Background Information
THE PURPOSE OF THE FOUNDATION IS TO ASSIST AND SUPPORT THE AMERICAN PSYCHIATRIC ASSOCIATION IN ACCOMPLISHING ITS EDUCATIONAL AND SCIENTIFIC PURPOSES BY PERFORMING FUNDRAISING FUNCTIONS AND BY DEVELOPING PUBLIC AND PROFESSIONAL ACTIVITIES TO ADVANCE EDUCATION IN MENTAL HEALTH AND PSYCHIATRIC DISORDERS, AND RELATED MENTAL HEALTH SUBJECTS AND TO PROMOTE THE TREATMENT OF PSYCHIATRIC ILLNESS.
Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion’s vision is to lead the way to a healthier world. The company’s spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything it does, Sunovion has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions. Headquartered in Marlborough, Mass., Sunovion is an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Europe Ltd., based in London, England, and Sunovion Pharmaceuticals Canada Inc., based in Mississauga, Ontario, are wholly-owned direct subsidiaries of Sunovion Pharmaceuticals Inc.